Physician profile
Usha Alfred
NPI 1538524996
$11,629.90
in general payments reported to CMS, 2019-2025
15 companies · $3,706 in 2025
The $3,706 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,274 · 2022: $1,817 · 2023: $2,432 · 2024: $2,401 · 2025: $3,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,758 · Consulting Fee: $648 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,758.38 |
| Consulting Fee | $647.50 |
| Education | $133.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,297.86 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,831.08 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $1,746.18 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,141.36 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,064.97 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $905.16 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $640.14 | 2023-2025 | Auvelity |
| Sage Therapeutics, LLC | $250.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $186.56 | 2021-2025 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $173.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $168.26 | 2025 | Spravato |
| Tris Pharma INC | $69.67 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Indivior INC. | $64.81 | 2023-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $64.29 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $26.01 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Alfred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.